Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NisLux
- Development stage
- Preclinical
- Lead developer
- Johns Hopkins Bloomberg School of Public Health
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intravenous
01
Overview
NisLux is an engineered, bioluminescent strain of *Escherichia coli* Nissle 1917 (EcN) developed as a research tool to study bacterial tropism in solid tumors. Created by researchers at the Johns Hopkins Bloomberg School of Public Health, the strain is integrated with a *luxCDABE* cassette, which enables non-invasive detection and quantification of the bacteria within tissues via luminescence. NisLux leverages the natural oncotropic properties of EcN, which selectively colonizes the hypoxic and immunosuppressed environments of the tumor microenvironment (TME). In preclinical murine models of melanoma and colorectal cancer, NisLux has demonstrated the ability to enrich at tumor sites at concentrations significantly higher than in healthy background tissue, making it a valuable model for investigating intratumoral microbiota and the potential delivery of therapeutic payloads directly to cancerous lesions.
- Other names
- E. coli Nissle 1917 luxCDABEluminescent E. coli Nissle 1917
02
Targets
PS (Phosphatidylserine)Lipid II
Beyond the preview
Go deeper on NisLux.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NisLux.